Zobrazeno 1 - 10
of 64
pro vyhledávání: ''
Autor:
Ang Li, Jason C. Chandler, Davey B. Daniel, Félix Couture, Sunil Babu, Vijay Gunuganti, Maen A. Hussein, Robert M. Jotte, Samer Kasbari, Michael McCleod, Edward B. Garon, Justin N. Baker, Nivedita Aanur, Lawrence H. Einhorn, Leora Horn, Ben C. Creelan, Petros Nikolinakos, George P. Keogh, David R. Spigel, Craig Reynolds, Natasha B. Leighl, David M. Waterhouse, George R. Blumenschein
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(33)
PURPOSE Limited data exist on the optimal duration of immunotherapy, including for non–small-cell lung cancer (NSCLC). We present an exploratory analysis of CheckMate 153, a largely community-based phase IIIb/IV study, to evaluate the impact of 1-y
Autor:
Angeles Alvarez Secord, Gini F. Fleming, Peter G. Rose, Krishnansu S. Tewari, Paul DiSilvestro, Matthew A. Powell, David S. Alberts, Linda Van Le, Susan A. Davidson, Keiichi Fujiwara, Mark F. Brady, Stephen C. Rubin, Robert S. Mannel, Helen Q. Huang, Lari Wenzel, Heidi J. Gray, David E. Cohn, Wenxin Zheng, Joan L. Walker, Carol Aghajanian, Tashanna Myers
Publikováno v:
J Clin Oncol
PURPOSE To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma. METHODS Eligible patients were randomly assigned to six cycles
Autor:
Sara Campora, Franca Avino, Andrea Decensi, Maria Digennaro, Anna Cariello, Davide Serrano, Marilena Petrera, Daniela Branchi, Matteo Lazzeroni, Luca Boni, Katia Cagossi, Tania Buttiron Webber, Marcella Gulisano, Graziella Pinotti, Fabio Falcini, Silvia Caviglia, Bernardo Bonanni, Cristiana Taverniti, Matteo Puntoni, Maria Grazia Pacquola, Aliana Guerrieri-Gonzaga, Laura Cortesi
Publikováno v:
Journal of Clinical Oncology
PURPOSE Tamoxifen administered for 5 years at 20 mg/d is effective in breast cancer treatment and prevention, but toxicity has limited its broad use. Biomarker trials showed that 5 mg/d is not inferior to 20 mg/d in decreasing breast cancer prolifera
Autor:
Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci
Publikováno v:
Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipi
Autor:
Javier Sastre, Ruth Vera, Rafael López, Jose Ignacio Martin Valades, Roberto Pedro Diaz Beveridge, Teresa Macarulla, J. Martínez-Galán, Sofia Perea, Immaculada Ales, Adelaida La Casta, Margarita Reboredo, Roberto Pazo-Cid, Manuel Hidalgo, Andres J. Muñoz Martín, Fernando Rivera, Carmen Guillén-Ponce
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Purpose Gemcitabine plus nanoparticle albumin-bound (NAB) paclitaxel (GA) significantly improved survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and a Karnofsky performance status (PS) of 7
Autor:
Bettina Peuser, Swantje Held, Thomas Kirchner, Ursula Vehling-Kaiser, Ingo Schwaner, Ullrich Graeven, J. Freiberg-Richter, Andreas Jung, Sebastian Stintzing, Christina Peveling genannt Reddemann, G. Schuch, Volker Heinemann, Claudio Denzlinger, Michael Schenk, Aio Krk Investigators, Arndt Stahler, Thomas Decker, Ludwig Fischer von Weikersthal, Xelaviri, Dominik Paul Modest, Clemens Giessen-Jung, Jens Uhlig
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(1)
Purpose The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectal cancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of i
Autor:
Joseph A. Sparano, William C. Wood, Edith A. Perez, Nancy E. Davidson, Tom Saphner, Fengmin Zhao, Jennifer A. Ligibel, George W. Sledge, Antonio C. Wolff, Silvana Martino
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(21)
Purpose To determine long-term outcomes in a clinical trial evaluating the role of taxane type and schedule in operable breast cancer and evaluate the impact of obesity and black race on outcome. Patients and Methods A total of 4,954 eligible women w
Autor:
Bruce G. Redman, Elizabeth R. Plimack, Ulka N. Vaishampayan, Theodore F. Logan, Kim Margolin, David F. McDermott, Timothy M. Kuzel, Michael R. Harrison, Robert J. Motzer, Hans J. Hammers, Ian M. Waxman, Brian I. Rini, Alexandre Lambert, Saby George, Harry A. Drabkin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13)
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu
Autor:
Yasushi Omuro, Akihito Tsuji, Jifeng Feng, Toshihiko Doi, Guo-ping Sun, Atsushi Ohtsu, Ik-Joo Chung, Yung-Jue Bang, Kun-Huei Yeh, Rui-Hua Xu, Shukui Qin, Hyun Cheol Chung, Taroh Satoh, Jianming Xu, Akihira Mukaiyama, Jin Li, Mikiro Kobayashi, Hiroto Miwa, Jinwan Wang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(19)
Purpose In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) –positive tumors. The role of anti-HER2 agents, including lapatinib, in this
Autor:
Raju Titus Chacko, Dinesh C. Doval, Brooke Esteves, Dmitry Nosov, Alexei A. Lyulko, William Slichenmyer, A. A. Anischenko, Andrew Strahs, Oleg Lipatov, Pankaj Bhargava
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(14)
Purpose The antitumor activity and safety of tivozanib, which is a potent and selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, was assessed in patients with advanced/metastatic renal cell carcinoma (RCC). Patients and Me